Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer
复制标题
DOI：
10.1200/jco.2005.09.077
复制
发表时间：
2005-05-20
影响因子：
45.3
通讯作者：
van de Vijver, MJ
中科院分区：
文献类型：
--
作者：
Hannemann, J;Oosterkamp, HM;van de Vijver, MJ
目的：目前，临床上缺乏预测原发性乳腺癌对阿霉素-环磷酰胺（AC）或阿霉素-多西他赛（AD）反应的有用标志物。我们研究了原发肿瘤的基因表达谱是否可以用来预测治疗反应，以任何这些chemotherapy regimens.Patients和方法在一个单一的机构，随机，II期试验，局部晚期乳腺癌患者接受了6个疗程的AC（n = 24）或AD（n = 24）新辅助化疗。基因表达谱是从治疗前获得的芯针活检中产生的，并与原发性肿瘤对化疗的反应相关。此外，治疗前的基因表达谱进行了比较与化疗后残留的肿瘤。结果10（20%）的48例患者表现出（近）的原发肿瘤治疗后病理完全缓解。所有患者或AC或AD组均未发现与缓解相关的基因表达模式。化疗后切除的肿瘤的预处理活检和肿瘤的比较显示，在肿瘤的基因表达的差异，表现出部分缓解，但不是在肿瘤，不响应chemical.Conclusion没有基因表达谱预测的反应，原发性乳腺癌AC或AD为基础的新辅助化疗可以检测到在这个中期分析。基因表达可能存在更微妙的差异，但只有通过研究更大的患者群体才能可靠地确定。乳腺肿瘤对新辅助化疗的反应导致基因表达的改变。(c)2005年，美国临床肿瘤学会。
Purpose At present, clinically useful markers predicting response of primary breast carcinomas to either doxorubicin-cyclophosphamide (AC) or doxorubicin-docetaxel (AD) are lacking. We investigated whether gene expression profiles of the primary tumor could be used to predict treatment response to either of those chemotherapy regimens.Patients and Methods Within a single-institution, randomized, phase II trial, patients with locally advanced breast cancer received six courses of either AC (n = 24) or AD (n = 24) neoadjuvant chemotherapy. Gene expression profiles were generated from core-needle biopsies obtained before treatment and correlated with the response of the primary tumor to the chemotherapy administered. Additionally, pretreatment gene expression profiles were compared with those in tumors remaining after chemotherapy.Results Ten (20 %) of 48 patients showed a (near) pathologic complete remission of the primary tumor after treatment. No gene expression pattern correlating with response could be identified for all patients or for the AC or AD groups separately. The comparison of the pretreatment biopsy and the tumor excised after chemotherapy revealed differences in gene expression in tumors that showed a partial remission but not in tumors that did not respond to chemotherapy.Conclusion No gene expression profile predicting the response of primary breast carcinomas to AC- or AD-based neoadjuvant chemotherapy could be detected in this interim analysis. More subtle differences in gene expression are likely to be present but can only be reliably identified by studying a larger group of patients. Response of a breast tumor to neoadjuvant chemotherapy results in alterations in gene expression. (c) 2005 by American Society of Clinical Oncology.